TY - JOUR
T1 - Phosphate homeostasis in Bartter syndrome
T2 - a case–control study
AU - Bettinelli, Alberto
AU - Viganò, Cristina
AU - Provero, Maria Cristina
AU - Barretta, Francesco
AU - Albisetti, Alessandra
AU - Tedeschi, Silvana
AU - Scicchitano, Barbara
AU - Bianchetti, Mario G.
PY - 2014
Y1 - 2014
N2 - Background: Bartter patients may be hypercalciuric. Additional abnormalities in the metabolism of calcium, phosphate, and calciotropic hormones have occasionally been reported.Methods: The metabolism of calcium, phosphate, and calciotropic hormones was investigated in 15 patients with Bartter syndrome and 15 healthy subjects.Results: Compared to the controls, Bartter patients had significantly reduced plasma phosphate {mean [interquartile range]:1.29 [1.16–1.46] vs. 1.61 [1.54–1.67] mmol/L} and maximal tubular phosphate reabsorption (1.16 [1.00–1.35] vs. 1.41 [1.37–1.47] mmol/L) and significantly increased parathyroid hormone (PTH) level (6.1 [4.5–7.7] vs. 2.8 [2.2–4.4] pmol/L). However, patients and controls did not differ in blood calcium, 25-hydroxyvitamin D, alkaline phosphatase, and osteocalcin levels. In patients, an inverse correlation (P <0.05) was noted between total plasma calcium or glomerular filtration rate and PTH concentration. A positive correlation was also noted between PTH and osteocalcin concentrations (P <0.005), as well as between chloriduria or natriuria and phosphaturia (P <0.001). No correlation was noted between calciuria and PTH concentration or between urinary or circulating phosphate and PTH.Conclusions: The results of this study demonstrate a tendency towards renal phosphate wasting and elevated circulating PTH levels in Bartter patients.
AB - Background: Bartter patients may be hypercalciuric. Additional abnormalities in the metabolism of calcium, phosphate, and calciotropic hormones have occasionally been reported.Methods: The metabolism of calcium, phosphate, and calciotropic hormones was investigated in 15 patients with Bartter syndrome and 15 healthy subjects.Results: Compared to the controls, Bartter patients had significantly reduced plasma phosphate {mean [interquartile range]:1.29 [1.16–1.46] vs. 1.61 [1.54–1.67] mmol/L} and maximal tubular phosphate reabsorption (1.16 [1.00–1.35] vs. 1.41 [1.37–1.47] mmol/L) and significantly increased parathyroid hormone (PTH) level (6.1 [4.5–7.7] vs. 2.8 [2.2–4.4] pmol/L). However, patients and controls did not differ in blood calcium, 25-hydroxyvitamin D, alkaline phosphatase, and osteocalcin levels. In patients, an inverse correlation (P <0.05) was noted between total plasma calcium or glomerular filtration rate and PTH concentration. A positive correlation was also noted between PTH and osteocalcin concentrations (P <0.005), as well as between chloriduria or natriuria and phosphaturia (P <0.001). No correlation was noted between calciuria and PTH concentration or between urinary or circulating phosphate and PTH.Conclusions: The results of this study demonstrate a tendency towards renal phosphate wasting and elevated circulating PTH levels in Bartter patients.
KW - Bartter syndrome
KW - Calcium
KW - Hypophosphatemia
KW - Maximal tubular reabsorption of phosphate
KW - Parathyroid hormone
UR - http://www.scopus.com/inward/record.url?scp=84930744956&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84930744956&partnerID=8YFLogxK
U2 - 10.1007/s00467-014-2846-z
DO - 10.1007/s00467-014-2846-z
M3 - Article
C2 - 24902942
AN - SCOPUS:84930744956
VL - 29
SP - 2133
EP - 2138
JO - Pediatric Nephrology
JF - Pediatric Nephrology
SN - 0931-041X
IS - 11
ER -